GlassScriptPhysician profile
Sarah M Nease
NPI 1891760278
$6,443.00
in general payments reported to CMS, 2019-2025
25 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $237 · 2021: $608 · 2022: $985 · 2023: $1,191 · 2024: $1,355 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,875.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $945.92 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $759.85 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $643.54 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $596.09 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $540.71 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $512.92 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $444.59 | 2023-2025 | Avvigo Guidance System, Rotapro, Watchman Access System |
| Pfizer INC. | $228.55 | 2023-2025 | |
| Novo Nordisk INC | $207.10 | 2023-2025 | Wegovy, Ozempic |
| Amgen INC. | $174.23 | 2019-2021 | |
| Heartflow, INC. | $161.45 | 2024-2025 | |
| Amarin Pharma, INC. | $157.93 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $148.54 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $137.71 | 2023-2024 | Inpefa |
| Medtronic, INC. | $131.00 | 2025 | Corevalve Evolut R |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $119.01 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $111.67 | 2025 | |
| Bridgebio Pharma, INC. | $91.78 | 2025 | Attruby |
| Scpharmaceuticals INC. | $86.58 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.45 | 2021-2023 | Lifevest |
| Alnylam Pharmaceuticals INC. | $68.60 | 2022-2025 | Onpattro |
| Abbott Laboratories | $46.47 | 2021-2024 | Navitor |
| Recor Medical INC | $24.90 | 2025 | Paradise Ultrasound Renal Denervation System |
| Esperion Therapeutics, INC. | $11.72 | 2021 | |
| Glaxosmithkline, LLC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Nease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.